Calcium release-activated calcium (CRAC) channels have been the target of drug discovery
for many years. The identification of STIM and Orai proteins as key components of CRAC
channels greatly facilitated this process because their co-expression in cell lines produced
electrophysiological currents (I CRAC) much larger than those in native cells, making it
easier to confirm and characterize the effects of modulatory compounds. A driving force in
the quest for CRAC channel drugs has been the immunocompromised phenotype displayed …